Development of potential antidotes for arsenicals

A compound having a structure represented by a formula:

• wherein each of R1a, R1b, R1c, R1d, and R1e is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R2 and R3 is independently selected from hydrogen and C1-C4 alkyl;
• wherein Cy1 is a structure having a formula selected from:
• wherein n, when present, is 0 or 1;
• wherein Z, when present, is selected from —O—, —S—, and —NR20—;
• wherein R20, when present, is selected from hydrogen and C1-C4 alkyl;
• wherein each of R10a, R10b, R10c, R10d, R10e, and R10f, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R11a and R11b, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R12a, R12b, R12c, and R12d, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• and
• wherein R13, when present, is selected from —OH, —NH2, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
• and
• wherein Cy2 is a structure having a formula selected from:
• wherein m, when present, is 0 or 1;
• wherein Q, when present, is selected from —O—, —S—, and —NR21—;
• wherein R21, when present, is selected from hydrogen and C1-C4 alkyl;
• wherein each of R14a, R14b, R14c, R14d, R14e, and R14f, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R15a and R15b, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R16a, R16b, R16c, and R16d, when present, is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• and
• wherein R17, when present, is selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, —CO2H, and —CO2 (C1-C4 alkyl),
• provided that when Cy1 is
• and at least seven of R10a, R10b, R10c, R10d, R10e, R10f, R11a, and R11b are hydrogen, then each of R1a, R1c, and R1e is halogen,
• provided that when Cy1 is
• then Cy2 is
• provided that when Cy1 is
• and Cy2 is
• then R17 is a non-hydrogen group, and
• provided that when Cy1 is
• Cy2 is
• and at least seven of R14a, R14b, R14c, R14d, R14e, R14f, R15a, and R15b are hydrogen, then each of R12a, R12b, R12c, and R12d is hydrogen,
• or a pharmaceutically acceptable salt thereof.